The Top 5 Biosimilars Articles for the Week of June 4

The Center for Biosimilars® recaps the top 5 articles for the week of June 4, 2018.


Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of June 4.

Number 5: Mylan and its partner Biocon received a Complete Response Letter from the FDA for their follow-on insulin glargine referencing Lantus.

Number 4: Celltrion has reported positive results of a study of a subcutaneous formulation of its biosimilar infliximab, Inflectra, in patients with Crohn disease.

Number 3: The FDA published new draft guidance that clarifies the types of formal meetings that biosimilar applicants can hold with the agency.

Number 2: During the 2018 American Society of Clinical Oncology Annual Meeting, researchers presented on new directions in anticancer and supportive care biosimilars.

Number 1: The FDA has approved its first pegfilgrastim biosimilar, Fulphila, referencing Neulasta.

Finally, last week, our e-newsletter asked whether you that US payers should encourage greater use of biosimilars.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit

Related Videos
andre harvin
Andre Harvin, PharmD
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Ian Henshaw
Nabil Saba
Paul Reider
Julie M. Reed
Sonia T. Oskouei, PharmD, BCMAS, DPLA0
Eric Tichy, PharmD, MBA
Julie M. Reed
Related Content
© 2023 MJH Life Sciences

All rights reserved.